Open AccessPARADOXICAL CROHN’S DISEASE – MYTH OR REALITY?
Author(s) -
Cristina Pomîrleanu,
Cătălina Mihai,
Codrina Ancuţa
Publication year - 2017
Publication title -
romanian journal of rheumatology
Language(s) - English
Resource type - Journals
eISSN - 2069-6086
pISSN - 1843-0791
DOI - 10.37897/rjr.2017.1.9
Subject(s) - medicine , etanercept , adalimumab , ankylosing spondylitis , crohn's disease , infliximab , inflammatory bowel disease , ustekinumab , disease , natalizumab , discontinuation , paradoxical reaction , immunology , tumor necrosis factor alpha , gastroenterology , pathology , tuberculosis
We report the clinical case of an emergent Crohn’s disease (CD) as a paradoxical effect after 24 months of successfully treatment with etanercept for active ankylosing spondylitis in a young women. Despite rapid and sustained response of articular disease (remission achieved as soon as three months and maintained through the entire period of administration), new onset intestinal manifestations developed during biological therapy. A complex assessment comprising clinical, endoscopic and histopathologic evaluation, associated with high levels of fecal calprotectin confirmed drug-induced inflammatory bowel disease (IBD) compatible with CD. Although optimal treatment strategy is not yet validated, discontinuation of putative etanercept and cycling to a monoclonal anti-TNF antibody (adalimumab) demonstrated positive outcomes for both articular and IBD. New onset CD may be considered as an immune-mediated injury induced etanercept and should be considered in any patient with spondylarthritis in whom IBD develops with a clear temporal relationship with TNF inhibitors, especially etanercept.